Key Points
- Oruka Therapeutics SVP Arjun Agarwal sold 9,999 shares on July 13 at an average price of $84.63, generating about $846,215. After the sale, he still owned 15,312 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
- Agarwal has been actively selling shares in recent weeks, including multiple transactions in June and May, with the July sale representing a 39.5% reduction in his ownership stake.
- Analysts remain broadly bullish on ORKA, with 10 Buy ratings and one Sell rating, and a consensus price target of $134.30. The stock recently traded around $84.56, well above its 50-day and 200-day moving averages.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction on Monday, July 13th. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the sale, the senior vice president directly owned 15,312 shares of the company's stock, valued at approximately $1,295,854.56. This trade represents a 39.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65.
- On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
- On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total value of $659,481.48.
- On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total value of $607,830.30.
Oruka Therapeutics Price Performance
Shares of Oruka Therapeutics stock opened at $84.56 on Tuesday. The business has a 50-day simple moving average of $70.87 and a 200 day simple moving average of $51.87. Oruka Therapeutics, Inc. has a one year low of $12.84 and a one year high of $97.78. The firm has a market capitalization of $5.10 billion, a price-to-earnings ratio of -43.59 and a beta of -0.35.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.
Analyst Ratings Changes
A number of analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $120.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 23rd. UBS Group lifted their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, July 1st. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a "buy" rating in a report on Monday, April 27th. BTIG Research reissued a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Monday. Finally, Barclays upped their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an "overweight" rating in a report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $134.30.
Get Our Latest Stock Analysis on ORKA
Institutional Investors Weigh In On Oruka Therapeutics
Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Oruka Therapeutics during the 2nd quarter valued at $28,000. BNP Paribas Financial Markets boosted its holdings in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its holdings in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth $39,000. Institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
